MYX 3.19% $4.85 mayne pharma group limited

Fundamentals Are Strong, page-63

  1. 20,509 Posts.
    lightbulb Created with Sketch. 2043

    All assets and companies have a price where they are good value , fair value and overvalued. Hikma and SRX may indeed be great companies ( at these prices ) but if you have paid a price that is not good value , then investment returns will be impacted and for you it's only as great as the return you extract. Dang, I find your posts a little contradictory , or perhaps I perceive them as having a strong comfirmation bias. You talk about the changes in the EV of Mayne as if it's some true reflection of value ( when it is simply driven by the short term market Sp, but when it comes to your holdings such as Hikma you ignore the fact the market has sliced 30% of the Ev and don't look at the EV change in the same way. Same goes for SRX. In the end we can argue until we discuss risks and opportunities , however the ultimate measure is our entry and exit prices and the return we can extract. SRX may be a great company that offers good return potential but if you for example bought at 25 dollars that next 55% return the stock provides is worth zero to you .
 
watchlist Created with Sketch. Add MYX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.